

Iftekhar Mahmood

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7808648/publications.pdf>

Version: 2024-02-01

80
papers

1,908
citations

304368

22
h-index

288905

40
g-index

80
all docs

80
docs citations

80
times ranked

1422
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Peptides: When Is the Assessment of Certain Factors Warranted?. <i>Antibodies</i> , 2022, 11, 1.	1.2	5
2	A Simple Method for the Prediction of Human Concentrationâ€“Time Profiles and Pharmacokinetics of Antibodyâ€“Drug Conjugates (ADC) from Rats or Monkeys. <i>Antibodies</i> , 2022, 11, 42.	1.2	1
3	Interspecies Scaling of Antibodyâ€“Drug Conjugates (ADC) for the Prediction of Human Clearance. <i>Antibodies</i> , 2021, 10, 1.	1.2	4
4	Clinical Pharmacology of Antibody-Drug Conjugates. <i>Antibodies</i> , 2021, 10, 20.	1.2	16
5	Spreadsheetâ€“Based Minimal Physiological Models for the Prediction of Clearance of Therapeutic Proteins in Pediatric Patients. <i>Journal of Clinical Pharmacology</i> , 2021, 61, S108-S116.	1.0	3
6	A Single Animal Species-Based Prediction of Human Clearance and First-in-Human Dose of Monoclonal Antibodies: Beyond Monkey. <i>Antibodies</i> , 2021, 10, 35.	1.2	4
7	Effect of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Antibodyâ€“Drug Conjugates (ADCs). <i>Antibodies</i> , 2021, 10, 40.	1.2	2
8	Extrapolation of Drug Clearance in Children â‰¥2 Years of Age from Empirical Models Using Data from Children (>2 Years) and Adults. <i>Drugs in R and D</i> , 2020, 20, 1-10.	1.1	8
9	A GFR-Based Method to Predict the Effect of Renal Impairment on the Exposure or Clearance of Renally Excreted Drugs: A Comparative Study Between a Simple GFR Method and a Physiologically Based Pharmacokinetic Model. <i>Drugs in R and D</i> , 2020, 20, 377-387.	1.1	5
10	Prediction of Clearance of Monoclonal and Polyclonal Antibodies and Non-Antibody Proteins in Children: Application of Allometric Scaling. <i>Antibodies</i> , 2020, 9, 40.	1.2	10
11	Considerations for pharmacokinetic assessment of immunoglobulins: Gammagard in very low birth weight neonates with and without baseline-correction. <i>International Immunopharmacology</i> , 2020, 82, 106358.	1.7	1
12	Considerations for Optimizing Dosing of Immunoglobulins Based on Pharmacokinetic Evidence. <i>Antibodies</i> , 2020, 9, 24.	1.2	13
13	Modelâ€“Based Evaluation of Linear Limited and Bayesian Sparse Sampling for Therapeutic Monitoring of Recombinant Coagulation Factor IX. <i>Journal of Clinical Pharmacology</i> , 2020, 60, 1453-1460.	1.0	0
14	Prediction of Clearance in Children from Adults Following Drugâ€“Drug Interaction Studies: Application of Age-Dependent Exponent Model. <i>Drugs in R and D</i> , 2020, 20, 47-54.	1.1	7
15	Population pharmacokinetics of immunoglobulin intravenous preparation in very low birth weight neonates. <i>International Immunopharmacology</i> , 2020, 80, 106192.	1.7	3
16	Clinical Pharmacology Review of Plasmaâ€“Derived and Recombinant Protein Products: CBER Experience and Perspectives on Modelâ€“Informed Drug Development. <i>Haemophilia</i> , 2019, 25, e240-e246.	1.0	8
17	A Comparative Study Between Allometric Scaling and Physiologically Based Pharmacokinetic Modeling for the Prediction of Drug Clearance From Neonates to Adolescents. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 189-197.	1.0	34
18	Initiation of Pediatric Clinical Trials for Coagulation Factors: Application of Pharmacokinetics and Allometry to Firstâ€“Pediatric Dose Selection. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 829-834.	1.0	5

#	ARTICLE	IF	CITATIONS
19	Prediction of Clearance and Dose of Midazolam in Preterm and Term Neonates: A Comparative Study Between Allometric Scaling and Physiologically Based Pharmacokinetic Modeling. <i>American Journal of Therapeutics</i> , 2019, 26, e32-e37.	0.5	20
20	Multistep Unified Models Using Prior Knowledge for the Prediction of Drug Clearance in Neonates and Infants. <i>Journal of Clinical Pharmacology</i> , 2018, 58, 877-884.	1.0	7
21	Age- and Bodyweight-dependent Allometric Exponent Model for Scaling Clearance and Maintenance Dose of Theophylline From Neonates to Adults. <i>Therapeutic Drug Monitoring</i> , 2018, 40, 635-641.	1.0	10
22	Prediction of tissue concentrations of monoclonal antibodies in mice from plasma concentrations. <i>Regulatory Toxicology and Pharmacology</i> , 2018, 97, 57-62.	1.3	1
23	Misconceptions and issues regarding allometric scaling during the drug development process. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 843-854.	1.5	22
24	Population Pharmacokinetics: Some Observations in Pediatric Modeling for Drug Clearance. <i>Clinical Pharmacokinetics</i> , 2017, 56, 1567-1576.	1.6	4
25	Prediction of Clearance, Volume of distribution, and Half-life of Drugs in Extremely Low to Low Birth Weight Neonates: An Allometric Approach. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2017, 42, 601-610.	0.6	12
26	Prediction of Clearance in Neonates and Infants (â‰¥ 3 Months of Age) for Drugs That Are Glucuronidated: A Comparative Study Between Allometric Scaling and Physiologically Based Pharmacokinetic Modeling. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 476-483.	1.0	25
27	Passive Immunoprophylaxis for the Protection of the Mother and Her Baby: Insights from In Vivo Models of Antibody Transport. <i>Journal of Immunology Research</i> , 2017, 2017, 1-8.	0.9	6
28	Prediction of Drug Clearance in Premature and Mature Neonates, Infants, and Children â‰¥2 Years of Age: A Comparison of the Predictive Performance of 4 Allometric Models. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 733-739.	1.0	30
29	Application of Allometric Principles in Pediatric Drug Development. , 2016, , 65-81.		0
30	Pharmacokinetic Considerations in Designing Pediatric Studies of Proteins, Antibodies, and Plasma-Derived Products. <i>American Journal of Therapeutics</i> , 2016, 23, e1043-e1056.	0.5	16
31	Prediction of Human Glomerular Filtration Rate from Preterm Neonates to Adults: Evaluation of Predictive Performance of Several Empirical Models. <i>AAPS Journal</i> , 2016, 18, 445-454.	2.2	10
32	Prediction of Antimalarial Drug Clearance in Children: A Comparison of Three Different Interspecies Scaling Methods. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2016, 41, 767-775.	0.6	3
33	<i>Pediatric Physiology</i> . , 2016, , 13-22.		1
34	Mechanistic versus allometric models for the prediction of drug clearance in neonates (<3 months) Tj ETQq0 0 0 rgBT /Overlock 10 Tf		10
35	Prediction of drug clearance in children: a review of different methodologies. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 573-587.	1.5	17
36	Prediction of glucuronidated drug clearance in pediatrics (â‰¥5 years): An allometric approach. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2015, 40, 53-59.	0.6	4

#	ARTICLE	IF	CITATIONS
37	Prediction of Drug Clearance in Children: an Evaluation of the Predictive Performance of Several Models. <i>AAPS Journal</i> , 2014, 16, 1334-1343.	2.2	44
38	Naive Pooled Data Approach for Pharmacokinetic Studies in Pediatrics With a Very Small Sample Size. <i>American Journal of Therapeutics</i> , 2014, 21, 269-274.	0.5	21
39	Transplacental Transfer of Hepatitis B Neutralizing Antibody during Pregnancy in an Animal Model: Implications for Newborn and Maternal Health. <i>Hepatitis Research and Treatment</i> , 2014, 2014, 1-7.	2.0	9
40	Vertical allometry: Fact or fiction?. <i>Regulatory Toxicology and Pharmacology</i> , 2014, 68, 468-474.	1.3	10
41	Dosing in Children: A Critical Review of the Pharmacokinetic Allometric Scaling and Modelling Approaches in Paediatric Drug Development and Clinical Settings. <i>Clinical Pharmacokinetics</i> , 2014, 53, 327-346.	1.6	106
42	Prediction of drug concentration-time profiles of therapeutic proteins in humans from animals. <i>Xenobiotica</i> , 2013, 43, 153-160.	0.5	2
43	Allometric scaling and prediction of concentration-time profiles of coagulation factors in humans from animals. <i>Xenobiotica</i> , 2013, 43, 774-779.	0.5	3
44	A population pharmacokinetic model of remifentanyl in pediatric patients using body-weight-dependent allometric exponents. <i>Drug Metabolism and Drug Interactions</i> , 2013, 28, 231-237.	0.3	13
45	Interspecies scaling of biliary excreted drugs: prediction of human clearance and volume of distribution. <i>Drug Metabolism and Drug Interactions</i> , 2012, 27, 157-64.	0.3	7
46	Prediction of Clearance and Volume of Distribution in the Obese from Normal Weight Subjects. <i>Clinical Pharmacokinetics</i> , 2012, 51, 527-542.	1.6	23
47	Prediction of drug concentration-time data in humans from animals: a comparison of three methods. <i>Xenobiotica</i> , 2012, 42, 756-765.	0.5	6
48	Prediction of Clearance and Volume of Distribution in the Obese from Normal Weight Subjects. <i>Clinical Pharmacokinetics</i> , 2012, 51, 527-542.	1.6	10
49	Evaluation of a morphine maturation model for the prediction of morphine clearance in children: how accurate is the predictive performance of the model?. <i>British Journal of Clinical Pharmacology</i> , 2011, 71, 88-94.	1.1	24
50	Response to the comments of Professors Anderson & Holford. <i>British Journal of Clinical Pharmacology</i> , 2011, 72, 521-523.	1.1	6
51	Pharmacokinetic Allometric Scaling of Oligonucleotides. <i>Nucleic Acid Therapeutics</i> , 2011, 21, 315-321.	2.0	9
52	A comparison of simple allometric and maturation models for the prediction of morphine clearance in pediatrics. <i>Drug Metabolism and Drug Interactions</i> , 2011, 26, 71-7.	0.3	0
53	Prediction of Clearance, Volume of Distribution and Half-life by Allometric Scaling and by use of Plasma Concentrations Predicted from Pharmacokinetic Constants: a Comparative Study. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 51, 905-910.	1.2	52
54	Prediction of Human Drug Clearance from Two Species: A Comparison of Several Allometric Methods. <i>Journal of Pharmaceutical Sciences</i> , 2010, 99, 1601-1613.	1.6	12

#	ARTICLE	IF	CITATIONS
55	Theoretical Versus Empirical Allometry: Facts Behind Theories Application to Pharmacokinetics. Journal of Pharmaceutical Sciences, 2010, 99, 2927-2933.	1.6	68
56	Prediction of drug clearance in children 3 months and younger: an allometric approach. Drug Metabolism and Drug Interactions, 2010, 25, 25-34.	0.3	18
57	Interspecies Scaling for the Prediction of Drug Clearance in Children. Clinical Pharmacokinetics, 2010, 49, 479-492.	1.6	19
58	Application of Fixed Exponent 0.75 to the Prediction of Human Drug Clearance: An Inaccurate and Misleading Concept. Drug Metabolism and Drug Interactions, 2009, 24, 57-82.	0.3	37
59	Population Pharmacokinetics with a Very Small Sample Size. Drug Metabolism and Drug Interactions, 2009, 24, 259-274.	0.3	21
60	Role of Fixed Coefficients and Exponents in the Prediction of Human Drug Clearance: How Accurate are the Predictions from One or Two Species?. Journal of Pharmaceutical Sciences, 2009, 98, 2472-2493.	1.6	23
61	Pharmacokinetic Allometric Scaling of Antibodies: Application to the First-In-Human Dose Estimation. Journal of Pharmaceutical Sciences, 2009, 98, 3850-3861.	1.6	74
62	Methods to determine pharmacokinetic profiles of therapeutic proteins. Drug Discovery Today: Technologies, 2008, 5, e65-e69.	4.0	7
63	Prediction of Drug Clearance in Children: Impact of Allometric Exponents, Body Weight, and Age. Therapeutic Drug Monitoring, 2007, 29, 271-278.	1.0	73
64	Drug Interaction Studies of Therapeutic Proteins or Monoclonal Antibodies. Journal of Clinical Pharmacology, 2007, 47, 1540-1554.	1.0	69
65	Application of allometric principles for the prediction of pharmacokinetics in human and veterinary drug development. Advanced Drug Delivery Reviews, 2007, 59, 1177-1192.	6.6	145
66	Prediction of drug clearance in children from adults: a comparison of several allometric methods. British Journal of Clinical Pharmacology, 2006, 61, 545-557.	1.1	121
67	Prediction of human drug clearance from animal data: Application of the rule of exponents and the corrected intercept method™ (FCIM). Journal of Pharmaceutical Sciences, 2006, 95, 1810-1821.	1.6	30
68	Interspecies Scaling of Biliary Excreted Drugs: A Comparison of Several Methods**The views expressed in this article are those of the author and do not reflect the official policy of the FDA. No official support or endorsement by the FDA is intended or should be inferred.. Journal of Pharmaceutical Sciences, 2005, 94, 883-892.	1.6	44
69	Pharmacokinetic and Pharmacodynamic Considerations in the Development of Therapeutic Proteins. Clinical Pharmacokinetics, 2005, 44, 331-347.	1.6	128
70	Interspecies Scaling of Protein Drugs: Prediction of Clearance from Animals to Humans. Journal of Pharmaceutical Sciences, 2004, 93, 177-185.	1.6	78
71	Selection of the First-Time Dose in Humans: Comparison of Different Approaches Based on Interspecies Scaling of Clearance. Journal of Clinical Pharmacology, 2003, 43, 692-697.	1.0	62
72	A Bayesian Approach for the Estimation of Pharmacokinetic Parameters in Children. American Journal of Therapeutics, 2003, 10, 88-92.	0.5	9

#	ARTICLE	IF	CITATIONS
73	Selection of the First-Time Dose in Humans: Comparison of Different Approaches Based on Interspecies Scaling of Clearance. <i>Journal of Clinical Pharmacology</i> , 2003, 43, 692-697.	1.0	1
74	Selection of the first-time dose in humans: comparison of different approaches based on interspecies scaling of clearance. <i>Journal of Clinical Pharmacology</i> , 2003, 43, 692-7.	1.0	19
75	Interspecies Scaling: Predicting Oral Clearance in Humans. <i>American Journal of Therapeutics</i> , 2002, 9, 35-42.	0.5	41
76	Selegiline transdermal system Somerset. <i>Current Opinion in Investigational Drugs</i> , 2002, 3, 1230-3.	2.3	2
77	Limited Sampling Model for the Estimation of Pharmacokinetic Parameters in Children. <i>Therapeutic Drug Monitoring</i> , 2000, 22, 532-536.	1.0	11
78	A comparative study of allometric scaling with plasma concentrations predicted by species-invariant time methods. , 1999, 20, 137-144.		26
79	Integration of in Vitro Data and Brain Weight in Allometric Scaling to Predict Clearance in Humans: Some Suggestions. <i>Journal of Pharmaceutical Sciences</i> , 1998, 87, 527-529.	1.6	24
80	Interspecies scaling of renally secreted drugs. <i>Life Sciences</i> , 1998, 63, 2365-2371.	2.0	75